Arcadia Biosciences Seeks Stockholder Nod for Reverse Split to Dodge Nasdaq Delisting and Unlock $3.5M Warrant Exercise

summarizeSummary

Arcadia Biosciences files preliminary proxy seeking stockholder approval for a reverse stock split to cure a Nasdaq bid price deficiency and for the issuance of shares underlying Series A-1 warrants from its June 2026 private placement, which would provide approximately $3.5 million in additional capital.

check_boxKey Events · Corporate Governance and Compliance · RKDA

• Reverse Stock Split Proposed

  To lift the stock price above $1.00 and cure a Nasdaq deficiency, the board seeks authority to implement a reverse stock split at a ratio between 1-for-2 and 1-for-10.

• Issuance Proposal for Series A-1 Warrants

  Stockholder approval is sought for the issuance of up to 3,883,496 shares upon exercise of Series A-1 Preferred Investment Options from the June 2026 private placement, which would yield approximately $3.5 million in gross proceeds at $0.91 per share.

• Nasdaq Delisting Risk

  After its stock traded below $1.00 for 30 consecutive business days, the company received a deficiency letter from Nasdaq; it has 180 days to regain compliance, and the reverse split is the primary mechanism to achieve this.

• Critical Cash Need

  With only $954,000 in cash as of March 31, 2026 and a going concern warning, the $3.5 million from warrant exercises is essential to fund operations; failure to approve the issuance proposal would cut off this capital source.

auto_awesomeAnalysis · RKDA · Energy & Transportation

With its stock at $0.62 and a Nasdaq delisting notice for sub-$1.00 bid price, Arcadia Biosciences is asking stockholders to approve a reverse stock split at a ratio between 1-for-2 and 1-for-10. The company also seeks approval to issue up to 3.88 million shares upon exercise of Series A-1 warrants from its June 2026 private placement, which would bring in roughly $3.5 million in additional capital. Both proposals are critical: the reverse split is the primary tool to regain Nasdaq compliance and avoid delisting, while the warrant exercise approval unlocks cash that the company—with only $954,000 on hand as of March 31, 2026 and a going concern warning—urgently needs. The proxy also includes a new equity incentive plan and routine governance items, but the reverse split and issuance proposals are the ones that will determine whether Arcadia can stay listed and funded.